Sino Biopharmaceutical co-led the oncology treatment developer's latest round, in which it raised over $91m in funding.

IP Group returned for the Bristol spinout's series D that will go to product development and commercialisation.

Bringing together researchers from Italy and the US, Chroma Medicine has emerged out of stealth with series A financing led by Cormorant Asset Management.

The neuromodulation-focused Stanford spinout increased its overall funding to $145m in a round led by Ascension Ventures.

Kindred Ventures led the healthcare services provider's series E round, valuing it at $4.6bn.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

BMW, Continental, Knorr-Bremse and VinFast backed the autonomous perception technology developer, which traces its roots to Technion.

The Stanford-backed blockchain development platform increased its valuation to $3.5bn in the series C round.

Takeda Ventures was among the participants in a $46.5m round closed nearly a year after its parent company launched a partnership with the Institut Curie spinout.

The gastrointestinal disorder drug developer was co-founded by researchers from Stanford University.